Harvard Pilgrim Health Care Home
  Learn more.
  Sign up for HPHConnect.
Medical Management
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Office Support
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

October 2017

Synagis for Upcoming RSV Season

With respiratory syncytial virus (RSV) season approaching, Harvard Pilgrim would like to remind providers of our policy regarding Synagis (palivizumab), an injection of antibodies used to protect high-risk infants from severe RSV disease. Harvard Pilgrim will require a prior authorization for Synagis during the 2017-2018 RSV season. Please keep in mind, however, that CVS Specialty is now Harvard Pilgrim’s preferred specialty vendor and will handle dispensing of this medication.

Synagis requires prior authorization and should be reserved for infants with a history of pre-term birth, and children with chronic lung disease or congenital heart disease. For members who qualify to receive five doses, the first dose is typically administered at the beginning of November and the last dose at the beginning of March, in order to provide protection into April.

To order Synagis, clinicians should complete the appropriate form, found on the Pharmacy prior authorization page on Harvard Pilgrim’s website. Massachusetts and New Hampshire providers will also need to fax a copy of the prescription to CVS Specialty at 800-323-2445, since their state-specific standard forms don’t include a prescription section. However, the form for providers in all other states allows for the capability of including prescription information.

For more information, please visit the Pharmacy section of Harvard Pilgrim’s provider website or call Clinical Pharmacy Services at 617-509-1786.

Email this article to a colleague   

Network Matters Archives

Download printer-friendly version


Harvard Pilgrim’s New “Estimate My Cost” Transparency Tool

Medicare Advantage: Important Information about Jimmo Settlement

Medicare Advantage Policy Updates for 2018

New Products and Benefits for 2018


Prior Authorization for Hip, Knee, and Shoulder Surgeries

Updates to Cholecystectomy Medical Review Criteria

Synagis for Upcoming RSV Season

Therapeutic Yoga for Chronic Pain and Other Conditions

P&T Committee Updates

Specialty Pharmacy Program Updates

ADHD Diagnosis and Follow-up Care


Reporting Modifier 50 for Bilateral Procedures

2018 CPT and HCPCS codes


Eric H. Schultz,
President and Chief Executive Officer

Robert Farias,
Senior Vice President, Network Strategy

Annmarie Dadoly,

Joseph O'Riordan,

Kristin Edmonston,
Production Coordinator